![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SNX30 |
Gene summary for SNX30 |
![]() |
Gene information | Species | Human | Gene symbol | SNX30 | Gene ID | 401548 |
Gene name | sorting nexin family member 30 | |
Gene Alias | ATG24A | |
Cytomap | 9q32 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q5VWJ9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
401548 | SNX30 | TD9 | Human | Lung | IAC | 2.40e-04 | 3.08e-01 | 0.088 |
401548 | SNX30 | RNA-P17T-P17T-6 | Human | Lung | IAC | 3.28e-02 | -4.80e-02 | 0.3385 |
401548 | SNX30 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 3.96e-05 | 2.09e-01 | -0.2116 |
401548 | SNX30 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.28e-03 | 2.61e-01 | -0.2119 |
401548 | SNX30 | RNA-P3T-P3T-4 | Human | Lung | IAC | 6.29e-03 | -1.02e-02 | 0.1859 |
401548 | SNX30 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.84e-14 | 5.38e-01 | -0.0166 |
401548 | SNX30 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 6.64e-22 | 6.05e-01 | -0.0132 |
401548 | SNX30 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.04e-18 | 5.07e-01 | -0.013 |
401548 | SNX30 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 8.46e-14 | 4.82e-01 | -0.0121 |
401548 | SNX30 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 3.11e-04 | 5.32e-01 | -0.0961 |
401548 | SNX30 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.30e-04 | 4.62e-01 | -0.0876 |
401548 | SNX30 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 4.16e-04 | 3.56e-01 | -0.0822 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SNX30 | insertion | Nonsense_Mutation | novel | c.675_676insTCCTTTATCTCCCTCTAGTTATACCCTTCTAGGTCTGGG | p.Ser225_Val226insSerPheIleSerLeuTerLeuTyrProSerArgSerGly | p.S225_V226insSFISL*LYPSRSG | Q5VWJ9 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
SNX30 | SNV | Missense_Mutation | rs370780169 | c.1114N>A | p.Val372Ile | p.V372I | Q5VWJ9 | protein_coding | tolerated(0.46) | probably_damaging(0.993) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SNX30 | SNV | Missense_Mutation | rs776097355 | c.435N>T | p.Glu145Asp | p.E145D | Q5VWJ9 | protein_coding | tolerated(0.27) | benign(0) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNX30 | SNV | Missense_Mutation | novel | c.388C>T | p.Arg130Cys | p.R130C | Q5VWJ9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SNX30 | SNV | Missense_Mutation | novel | c.940G>A | p.Glu314Lys | p.E314K | Q5VWJ9 | protein_coding | tolerated(0.52) | benign(0.171) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
SNX30 | SNV | Missense_Mutation | rs370780169 | c.1114G>A | p.Val372Ile | p.V372I | Q5VWJ9 | protein_coding | tolerated(0.46) | probably_damaging(0.993) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
SNX30 | SNV | Missense_Mutation | c.461N>A | p.Pro154His | p.P154H | Q5VWJ9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
SNX30 | SNV | Missense_Mutation | rs774859312 | c.1093N>T | p.Arg365Cys | p.R365C | Q5VWJ9 | protein_coding | tolerated(0.07) | benign(0.444) | TCGA-DM-A28A-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
SNX30 | SNV | Missense_Mutation | novel | c.662G>A | p.Arg221Lys | p.R221K | Q5VWJ9 | protein_coding | tolerated(0.43) | benign(0) | TCGA-4E-A92E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNX30 | SNV | Missense_Mutation | novel | c.782N>A | p.Arg261Gln | p.R261Q | Q5VWJ9 | protein_coding | tolerated(0.05) | benign(0.12) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |